President Trump implemented comprehensive import duties on pharmaceutical products Thursday through Truth Social announcements. Companies face 100 percent tariffs on branded and patented medications beginning October 1, 2025, unless they construct manufacturing facilities within American borders. Additional levies target furniture and automotive sectors with rates ranging from 25 to 50 percent across various product categories.
Indian pharmaceutical manufacturers confront substantial revenue threats from these policy changes. America represents the largest export destination for Indian drug companies, absorbing 31 percent of the nation's $27.9 billion pharmaceutical shipments during fiscal year 2024. Major firms generate between 30 and 50 percent of total earnings from American market operations.
The subcontinent supplies nearly half of all generic medications consumed by American patients. Uncertainty persists regarding whether specialized generic formulations will face similar trade restrictions under the new framework.
Indian pharmaceutical manufacturers confront substantial revenue threats from these policy changes. America represents the largest export destination for Indian drug companies, absorbing 31 percent of the nation's $27.9 billion pharmaceutical shipments during fiscal year 2024. Major firms generate between 30 and 50 percent of total earnings from American market operations.
The subcontinent supplies nearly half of all generic medications consumed by American patients. Uncertainty persists regarding whether specialized generic formulations will face similar trade restrictions under the new framework.
